Spots Global Cancer Trial Database for trametinib
Every month we try and update this database with for trametinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | NCT05668585 | Solid Tumors Melanoma NSCLC CRC ATC | CFT1946 Trametinib Cetuximab | 18 Years - | C4 Therapeutics, Inc. | |
| Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations | NCT05876806 | Cancer | Dabrafenib Trametinib | 19 Years - | Seoul St. Mary's Hospital | |
| Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma | NCT01979523 | Recurrent Uveal... Stage IV Uveal ... | Laboratory Biom... Pharmacological... Trametinib Uprosertib | 18 Years - | National Cancer Institute (NCI) | |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | NCT06346067 | Advanced or Met... | Naporafenib Dacarbazine Temozolomide Trametinib | 18 Years - 99 Years | Erasca, Inc. | |
| XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation | NCT05275374 | Cancer BRAF V600 Mutat... Melanoma Colorectal Canc... Thyroid Cancer Nonsmall Cell L... | XP-102 Trametinib | 18 Years - | Xynomic Pharmaceuticals, Inc. | |
| Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors | NCT05868629 | Rare Unresectab... | Non-investigati... | 6 Years - | Novartis | |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | NCT05358249 | KRAS G12C Mutan... Carcinoma, Non-... Carcinoma, Non-... Non-Small Cell ... Non-Small Cell ... Nonsmall Cell L... Colorectal Canc... Colorectal Carc... Colorectal Neop... Colorectal Tumo... Neoplasms, Colo... | JDQ443 trametinib Ribociclib cetuximab | 18 Years - | Novartis | |
| Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy | NCT05180825 | Grade 1 Glioma Mixed Glio-neur... Pleomorphic Xan... | Trametinib Vinblastine | 1 Month - 25 Years | University Hospital, Strasbourg, France | |
| Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | NCT02097225 | BRAF V600E Muta... BRAF V600K Muta... Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable So... | Dabrafenib Laboratory Biom... Onalespib Pharmacological... Trametinib | 18 Years - | National Cancer Institute (NCI) | |
| Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT01989598 | Recurrent Plasm... Refractory Plas... | Laboratory Biom... Pharmacological... Trametinib Uprosertib | 18 Years - | National Cancer Institute (NCI) | |
| A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors | NCT03266159 | Solid Tumours | GSK525762 Besyl... Trametinib tabl... | 18 Years - | GlaxoSmithKline | |
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | NCT04544111 | Thyroid Cancer Thyroid Cancer,... Papillary Thyro... Follicular Thyr... Hurthle Cell Tu... Poorly Differen... Hurthle Cell Th... | Trametinib Dabrafenib PDR001 | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Pilot Study on Trametinib for Surgical Unruptured AVMs | NCT06098872 | Arteriovenous M... | Trametinib tabl... | 18 Years - | University Health Network, Toronto | |
| "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)" | NCT05299580 | Melanoma | dabrafenib Trametinib | 18 Years - | Fondazione Melanoma Onlus | |
| Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain | NCT02039947 | Melanoma and Br... | Dabrafenib Trametinib | 18 Years - | Novartis | |
| A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia | NCT02016729 | Advanced Malign... Cancer Oncology Oncology Patien... Acute Myeloid L... | AMG 232 Trametinib | 18 Years - | Kartos Therapeutics, Inc. | |
| Treatment of NF1-related Plexiform Neurofibroma With Trametinib | NCT03741101 | Neurofibromatos... Child Neurofibroma, P... | Trametinib | 1 Year - 17 Years | Region Skane | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Pan Tumor Rollover Study | NCT03899155 | Cancer | Nivolumab Ipilimumab Cabozantinib Trametinib Relatlimab Nivolumab + Rel... Capecitabine Bevacizumab Temozolomide Rucaparib Daratumumab Regorafinib Leucovorin Fluorouracil Oxaliplatin Enzalutamide Sunitinib Pemetrexed Pembrolizumab | 18 Years - | Bristol-Myers Squibb | |
| Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients | NCT04967079 | Non Small Cell ... | Trametinib Anlotinib | 18 Years - 75 Years | Shanghai Chest Hospital | |
| Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma | NCT02910700 | Metastatic Mali... Metastatic Mela... Stage III Cutan... Stage IIIA Cuta... Stage IIIB Cuta... Stage IIIC Cuta... Stage IV Cutane... Unresectable Me... | Binimetinib Dabrafenib Encorafenib Laboratory Biom... Nivolumab Pharmacological... Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma | NCT04310397 | Pathologic Stag... Pathologic Stag... Pathologic Stag... | Dabrafenib Spartalizumab Therapeutic Con... Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | NCT04487106 | Recurrent Acute... Recurrent Chron... Recurrent Myelo... Refractory Acut... Refractory Chro... Refractory Myel... | Azacitidine Trametinib Venetoclax | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | NCT02684058 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Ipon... | Dabrafenib trametinib Carboplatin Vincristine | 12 Months - 17 Years | Novartis | |
| Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain | NCT02439411 | Malignant Melan... Malignant Melan... | Trametinib | 18 Years - | Grupo Español Multidisciplinar de Melanoma | |
| Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma | NCT05525273 | Craniopharyngio... | Oral dabrafenib... | 18 Years - | Skane University Hospital | |
| Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients | NCT02296996 | Malignant Melan... | Dabrafenib + Tr... | 18 Years - | Universitair Ziekenhuis Brussel | |
| Melanoma Metastasized to the Brain and Steroids | NCT03563729 | Malignant Melan... | Pembrolizumab I... Ipilimumab Inje... Nivolumab Injec... Encorafenib Binimetinib Dabrafenib Trametinib | 18 Years - | Herlev Hospital | |
| A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | NCT05849662 | Leukemia, Juven... JMML JCML Neurofibromatos... CBL Syndrome | Trametinib Azacitidine Fludarabine Cytarabine | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | NCT04185883 | Advanced Solid ... Kirsten Rat Sar... | Sotorasib Trametinib RMC-4630 Afatinib Pembrolizumab Panitumumab Carboplatin, pe... Atezolizumab Palbociclib MVASI® (bevaciz... TNO155 IV Chemotherapy... IV Chemotherapy... BI 1701963 AMG 404 Everolimus | 18 Years - 100 Years | Amgen | |
| Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | NCT01989585 | Clinical Stage ... Clinical Stage ... Malignant Solid... Metastatic Mela... Unresectable Me... | Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Echocardiograph... Laboratory Biom... Magnetic Resona... Multigated Acqu... Navitoclax Pharmacological... Trametinib | 18 Years - | National Cancer Institute (NCI) | |
| Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors | NCT02079740 | Metastatic Mali... Refractory Mali... Unresectable Ma... | Biopsy Biospecimen Col... Computed Tomogr... Magnetic Resona... Navitoclax Positron Emissi... Trametinib | 18 Years - | National Cancer Institute (NCI) | |
| Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer | NCT04739566 | Thyroid Gland A... | Dabrafenib Trametinib | 18 Years - | Saint Petersburg State University, Russia | |
| A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer | NCT02399943 | Colorectal Canc... KRAS Wildtype NRAS Wildtype BRAF Wildtype | Trametinib Panitumumab | 18 Years - | University Health Network, Toronto | |
| A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma | NCT03091257 | Multiple Myelom... | Dabrafenib Trametinib | 18 Years - | Massachusetts General Hospital | |
| Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases | NCT02974803 | Melanoma Brain Metastase... | Dabrafenib Trametinib | 18 Years - | Canadian Cancer Trials Group | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations | NCT01827384 | Advanced Malign... | Adavosertib Carboplatin Everolimus Temozolomide Trametinib Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | NCT05849662 | Leukemia, Juven... JMML JCML Neurofibromatos... CBL Syndrome | Trametinib Azacitidine Fludarabine Cytarabine | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | NCT06346067 | Advanced or Met... | Naporafenib Dacarbazine Temozolomide Trametinib | 18 Years - 99 Years | Erasca, Inc. | |
| Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | NCT02881242 | Hormone-Resista... Metastatic Pros... Recurrent Prost... Stage IV Prosta... | Laboratory Biom... Quality-of-Life... Trametinib | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection | NCT04666272 | Melanoma | dabrafenib trametinib | 18 Years - 100 Years | Novartis | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer | NCT02428270 | Pancreatic Canc... Adenocarcinoma | GSK2256098 Trametinib | 18 Years - | University Health Network, Toronto | |
| A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | NCT03076164 | Lung Adenocarci... Lung Cancer Lung Cancer Met... Lung Cancer Sta... Recurrent Lung ... Recurrent Lung ... | Trametinib Erlotinib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes | NCT03551626 | Malignant Melan... | Dabrafenib Trametinib | 18 Years - | Novartis | |
| Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas | NCT03631953 | Meningioma | Trametinib Alpelisib Blood sample MRI | 18 Years - | Assistance Publique Hopitaux De Marseille | |
| Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) | NCT01928940 | Solid Tumours | dabrafenib trametinib | 20 Years - | GlaxoSmithKline | |
| Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | NCT05440942 | Pancreatic Duct... | Trametinib Ruxolitinib Retifanlimab | 18 Years - | University of Miami | |
| Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma | NCT03754179 | Melanoma | Dabrafenib Trametinib Hydroxychloroqu... | 18 Years - | Universitair Ziekenhuis Brussel | |
| MCS110 With BRAF/MEK Inhibition in Patients With Melanoma | NCT03455764 | Melanoma | MCS110 Dabrafenib Trametinib | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma | NCT02967692 | Melanoma | Spartalizumab Placebo Dabrafenib Trametinib | 18 Years - | Novartis | |
| A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer | NCT04294160 | BRAF V600 Color... | Dabrafenib LTT462 Trametinib LXH254 TNO155 Spartalizumab Tislelizumab | 18 Years - | Novartis | |
| Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations | NCT05876806 | Cancer | Dabrafenib Trametinib | 19 Years - | Seoul St. Mary's Hospital | |
| Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia | NCT01907815 | Recurrent Adult... Untreated Adult... | Akt Inhibitor G... Laboratory Biom... Trametinib | 18 Years - | National Cancer Institute (NCI) | |
| Treatment of NF1-related Plexiform Neurofibroma With Trametinib | NCT03741101 | Neurofibromatos... Child Neurofibroma, P... | Trametinib | 1 Year - 17 Years | Region Skane | |
| Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery | NCT03148275 | Locally Advance... Metastatic Epit... Unresectable Ep... | Questionnaire A... Trametinib | 15 Years - | National Cancer Institute (NCI) | |
| An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread | NCT03377361 | Colorectal Canc... Colorectal Tumo... Colorectal Carc... Colorectal Neop... | Nivolumab Trametinib Ipilimumab Regorafenib | 18 Years - | Bristol-Myers Squibb | |
| Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer | NCT03825289 | Metastatic Panc... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa... | Hydroxychloroqu... Trametinib | 18 Years - | University of Utah | |
| Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC | NCT03333343 | EGFR-mutant Non... | EGF816 trametinib ribociclib LXH254 INC280 gefitinib | 18 Years - | Novartis | |
| A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | NCT02130466 | Melanoma Solid Tumors | Pembrolizumab Dabrafenib Trametinib Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer | NCT04507919 | Small Cell Lung... | Dabrafenib Trametininb | 18 Years - 99 Years | Novartis | |
| Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel | NCT01192165 | Cancer | Trametinib (GSK... Docetaxel Erlotinib Pemetrexed Carboplatin nab-Paclitaxel Cisplatin | 18 Years - | GlaxoSmithKline | |
| A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib | NCT02382549 | Melanoma | BRAF inhibitor 6MHP MEK inhibitor | 18 Years - | University of Virginia | |
| Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib | NCT02357732 | Metastatic Mela... | Nivolumab Trametinib Dabrafenib | 18 Years - | University of Pittsburgh | |
| UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib | NCT02140840 | Multiple Myelom... | Trametinib | 18 Years - | University of Arkansas | |
| A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration | NCT04201457 | Low Grade Gliom... High Grade Glio... Low Grade Gliom... | Dabrafenib Trametinib Hydroxychloroqu... | 1 Year - 30 Years | Pediatric Brain Tumor Consortium | |
| Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets | NCT01721603 | BRAFV600E Melan... | Dabrafenib Gamma Knife Rad... Trametinib | 18 Years - | University of California, San Francisco | |
| Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations | NCT02296112 | Recurrent Melan... Stage IIIB Mela... Stage IIIC Mela... Stage IV Melano... | trametinib laboratory biom... pharmacological... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy | NCT05180825 | Grade 1 Glioma Mixed Glio-neur... Pleomorphic Xan... | Trametinib Vinblastine | 1 Month - 25 Years | University Hospital, Strasbourg, France | |
| Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation | NCT02231775 | Stage IIIB Cuta... Stage IIIC Cuta... | Dabrafenib Laboratory Biom... Therapeutic Con... Trametinib | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma | NCT01767454 | Solid Tumours | Dabrafenib Trametinib Ipilimumab | 18 Years - | GlaxoSmithKline | |
| Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | NCT03975231 | BRAF NP_004324.... BRAF V600K Muta... Thyroid Gland A... | Dabrafenib Intensity-Modul... Trametinib | 18 Years - | City of Hope Medical Center | |
| A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC | NCT04452877 | Carcinoma, Non-... | Dabrafenib Trametinib | 18 Years - | Novartis | |
| Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). | NCT04566133 | Bile Duct Cance... Biliary Cancer Biliary Tract N... Cholangiocarcin... | Trametinib Hydroxychloroqu... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | NCT02684058 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Ipon... | Dabrafenib trametinib Carboplatin Vincristine | 12 Months - 17 Years | Novartis | |
| Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer | NCT03244956 | Metastatic Radi... | Trametinib Dabrafenib 131I rhTSH | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) | NCT04111458 | Solid Tumors, K... | BI 1701963 Trametinib | 18 Years - | Boehringer Ingelheim | |
| UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib | NCT02140840 | Multiple Myelom... | Trametinib | 18 Years - | University of Arkansas | |
| Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma | NCT05440942 | Pancreatic Duct... | Trametinib Ruxolitinib Retifanlimab | 18 Years - | University of Miami |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
